Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 5, Pages e002485
Publisher
BMJ
Online
2021-05-07
DOI
10.1136/jitc-2021-002485
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results
- (2020) Renata Ferrarotto et al. CLINICAL CANCER RESEARCH
- Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).
- (2020) Naomi Kiyota et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity
- (2020) Lauren K. Zebertavage et al. Scientific Reports
- Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
- (2020) Brendan Curti et al. Journal for ImmunoTherapy of Cancer
- Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial
- (2020) Ravindra Uppaluri et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
- (2020) Sean McBride et al. JOURNAL OF CLINICAL ONCOLOGY
- Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survival
- (2020) Chi T. Viet et al. ORAL ONCOLOGY
- Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
- (2020) Jonathan D. Schoenfeld et al. JAMA Oncology
- A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
- (2019) Alexander C. Huang et al. NATURE MEDICINE
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
- (2018) T R Cottrell et al. ANNALS OF ONCOLOGY
- Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy
- (2018) Ariel E. Marciscano et al. CLINICAL CANCER RESEARCH
- Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial
- (2018) Yungan Tao et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity
- (2018) Marka R. Crittenden et al. Scientific Reports
- Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial
- (2018) Maura L Gillison et al. LANCET
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Erratum to ‘Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy’ [Oral Oncol. 61 (2016) 166–176]
- (2017) R. Bryan Bell et al. ORAL ONCOLOGY
- Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
- (2016) Michael B. Bernstein et al. Nature Reviews Clinical Oncology
- A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma
- (2016) Todd Crocenzi et al. Journal for ImmunoTherapy of Cancer
- Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
- (2016) Kristina H. Young et al. PLoS One
- Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy
- (2015) Michael J Gough et al. Immunotherapy
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Clavien-Dindo Classification of Surgical Complications
- (2009) Pierre A. Clavien et al. ANNALS OF SURGERY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started